Free Trial

Veradigm (MDRX) Competitors

Veradigm logo
$5.18 +0.18 (+3.60%)
As of 09:41 AM Eastern

MDRX vs. SDGR, CERT, TDOC, GDRX, and HSTM

Should you buy Veradigm stock or one of its competitors? Veradigm's main competitors and comparable companies include Schrodinger (SDGR), Certara (CERT), Teladoc Health (TDOC), GoodRx (GDRX), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Veradigm compare to Schrodinger?

Veradigm (NASDAQ:MDRX) and Schrodinger (NASDAQ:SDGR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Veradigm has higher revenue and earnings than Schrodinger.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veradigm$1.53B0.40N/AN/AN/A
Schrodinger$269.20M8.10-$103.26M-$0.79N/A

In the previous week, Schrodinger had 11 more articles in the media than Veradigm. MarketBeat recorded 13 mentions for Schrodinger and 2 mentions for Veradigm. Schrodinger's average media sentiment score of 0.64 beat Veradigm's score of -0.36 indicating that Schrodinger is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veradigm
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Schrodinger
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Veradigm has a net margin of 0.00% compared to Schrodinger's net margin of -22.02%. Veradigm's return on equity of 0.00% beat Schrodinger's return on equity.

Company Net Margins Return on Equity Return on Assets
VeradigmN/A N/A N/A
Schrodinger -22.02%-18.12%-9.07%

79.1% of Schrodinger shares are owned by institutional investors. 2.3% of Veradigm shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Veradigm has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

Schrodinger has a consensus target price of $26.67, suggesting a potential downside of 9.70%. Given Schrodinger's stronger consensus rating and higher possible upside, analysts plainly believe Schrodinger is more favorable than Veradigm.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veradigm
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Schrodinger
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

Summary

Schrodinger beats Veradigm on 9 of the 14 factors compared between the two stocks.

How does Veradigm compare to Certara?

Certara (NASDAQ:CERT) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Veradigm has a net margin of 0.00% compared to Certara's net margin of -16.14%. Certara's return on equity of 3.36% beat Veradigm's return on equity.

Company Net Margins Return on Equity Return on Assets
Certara-16.14% 3.36% 2.31%
Veradigm N/A N/A N/A

Certara has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Veradigm has higher revenue and earnings than Certara.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Certara$425.76M4.15-$1.60M-$0.42N/A
Veradigm$1.53B0.40N/AN/AN/A

Certara currently has a consensus target price of $9.92, suggesting a potential downside of 14.29%. Given Certara's stronger consensus rating and higher probable upside, analysts clearly believe Certara is more favorable than Veradigm.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Certara
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.38
Veradigm
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Certara had 1 more articles in the media than Veradigm. MarketBeat recorded 3 mentions for Certara and 2 mentions for Veradigm. Certara's average media sentiment score of 0.96 beat Veradigm's score of -0.36 indicating that Certara is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Certara
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Veradigm
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

74.0% of Certara shares are owned by institutional investors. 1.1% of Certara shares are owned by company insiders. Comparatively, 2.3% of Veradigm shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Certara beats Veradigm on 11 of the 15 factors compared between the two stocks.

How does Veradigm compare to Teladoc Health?

Veradigm (NASDAQ:MDRX) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Veradigm has a net margin of 0.00% compared to Teladoc Health's net margin of -6.27%. Veradigm's return on equity of 0.00% beat Teladoc Health's return on equity.

Company Net Margins Return on Equity Return on Assets
VeradigmN/A N/A N/A
Teladoc Health -6.27%-11.63%-5.53%

76.8% of Teladoc Health shares are held by institutional investors. 2.3% of Veradigm shares are held by company insiders. Comparatively, 0.7% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Veradigm has higher earnings, but lower revenue than Teladoc Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veradigm$1.53B0.40N/AN/AN/A
Teladoc Health$2.47B0.65-$200.32M-$0.86N/A

Veradigm has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Teladoc Health has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Teladoc Health has a consensus price target of $8.53, indicating a potential downside of 3.09%. Given Teladoc Health's stronger consensus rating and higher probable upside, analysts clearly believe Teladoc Health is more favorable than Veradigm.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veradigm
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Teladoc Health
2 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, Teladoc Health had 8 more articles in the media than Veradigm. MarketBeat recorded 10 mentions for Teladoc Health and 2 mentions for Veradigm. Teladoc Health's average media sentiment score of 0.65 beat Veradigm's score of -0.36 indicating that Teladoc Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veradigm
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Teladoc Health
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Teladoc Health beats Veradigm on 9 of the 14 factors compared between the two stocks.

How does Veradigm compare to GoodRx?

Veradigm (NASDAQ:MDRX) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

GoodRx has lower revenue, but higher earnings than Veradigm.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veradigm$1.53B0.40N/AN/AN/A
GoodRx$785.23M1.55$30.44M$0.0489.00

GoodRx has a consensus target price of $4.15, suggesting a potential upside of 16.57%. Given GoodRx's stronger consensus rating and higher probable upside, analysts clearly believe GoodRx is more favorable than Veradigm.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veradigm
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08

In the previous week, GoodRx had 4 more articles in the media than Veradigm. MarketBeat recorded 6 mentions for GoodRx and 2 mentions for Veradigm. GoodRx's average media sentiment score of 0.46 beat Veradigm's score of -0.36 indicating that GoodRx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veradigm
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
GoodRx
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Veradigm has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

GoodRx has a net margin of 2.07% compared to Veradigm's net margin of 0.00%. GoodRx's return on equity of 7.22% beat Veradigm's return on equity.

Company Net Margins Return on Equity Return on Assets
VeradigmN/A N/A N/A
GoodRx 2.07%7.22%2.53%

63.8% of GoodRx shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 5.9% of GoodRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

GoodRx beats Veradigm on 13 of the 14 factors compared between the two stocks.

How does Veradigm compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

HealthStream has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

HealthStream has higher earnings, but lower revenue than Veradigm.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HealthStream$304.06M2.82$18.34M$0.7039.96
Veradigm$1.53B0.40N/AN/AN/A

HealthStream has a net margin of 6.25% compared to Veradigm's net margin of 0.00%. HealthStream's return on equity of 6.37% beat Veradigm's return on equity.

Company Net Margins Return on Equity Return on Assets
HealthStream6.25% 6.37% 4.37%
Veradigm N/A N/A N/A

HealthStream currently has a consensus target price of $36.00, indicating a potential upside of 28.71%. Given HealthStream's stronger consensus rating and higher probable upside, equities analysts plainly believe HealthStream is more favorable than Veradigm.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HealthStream
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Veradigm
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

69.6% of HealthStream shares are owned by institutional investors. 20.4% of HealthStream shares are owned by company insiders. Comparatively, 2.3% of Veradigm shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, HealthStream and HealthStream both had 2 articles in the media. HealthStream's average media sentiment score of 0.37 beat Veradigm's score of -0.36 indicating that HealthStream is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HealthStream
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Veradigm
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

HealthStream beats Veradigm on 11 of the 13 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDRX vs. The Competition

MetricVeradigmHealthcare Technology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$633.51M$1.98B$7.88B$11.82B
Dividend YieldN/A3.89%2.47%4.41%
P/E Ratio23.2542.1433.3329.96
Price / Sales0.415.188.125.37
Price / CashN/A15.7621.0222.32
Price / BookN/A5.794.803.87
Net IncomeN/A-$19.09M$3.52B$391.27M
7 Day Performance9.05%-6.15%-4.56%-3.90%
1 Month Performance3.60%-4.37%-2.78%-5.24%
1 Year Performance7.92%-11.27%0.12%-7.23%

Veradigm Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDRX
Veradigm
N/A$5.18
+3.6%
N/A+4.2%$633.51M$1.53B23.252,300
SDGR
Schrodinger
1.8728 of 5 stars
$29.69
-3.8%
$26.67
-10.2%
+67.4%$2.19B$255.87MN/A850
CERT
Certara
1.8008 of 5 stars
$11.77
-1.1%
$9.92
-15.7%
+38.9%$1.80B$418.84MN/A1,576
TDOC
Teladoc Health
1.4539 of 5 stars
$8.84
+1.7%
$8.53
-3.4%
+27.3%$1.61B$2.53BN/A5,600
GDRX
GoodRx
3.6405 of 5 stars
$3.60
+2.4%
$4.15
+15.4%
+19.9%$1.23B$796.85M89.90697

Related Companies and Tools


This page (NASDAQ:MDRX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners